Dr. Johnson on the Promise of DS-7300 in SCLC and Other Advanced Solid Tumors

Partner | Cancer Centers | <b>Sarah Cannon</b>

Melissa L. Johnson, MD, discusses the promise of DS-7300 in small cell lung cancer and other advanced solid tumors.

Melissa L. Johnson, MD, program director, Lung Cancer Research, lead, Solid Tumor Immune Effector Cellular Therapy Program, Sarah Cannon Research Institute, discusses the promise of DS-7300 in small cell lung cancer (SCLC) and other advanced solid tumors.

During the 2021 ESMO Congress, findings from a phase 1/2 trial (NCT04145622) were presented. The study is evaluating the safety and initial efficacy of DS-7300. The antibody-drug conjugate (ADC) is directed toward B7 homologue 3 (B7-H3), which is a transmembrane protein overexpressed in several cancers, such as lung, prostate, esophageal, breast, and head and neck cancers. The ADC utilizes a topoisomerase I inhibitor payload as its mechanism of action.

Among 70 patients who received various dosing levels of DS-7300, 15 derived a partial response with the agent. Responses were observed in patients with prostate cancer, SCLC, and esophageal squamous cell carcinoma, Johnson explains.

Notably, because B7-H3 is an immune checkpoint, knowledge generated in oncology with immunotherapy and other ADCs may inform the utility of DS-7300, Johnson concludes.